Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.

The pharmacogenomics journal - 1 Oct 2021

Ammar Helmi, Chadli Zohra, Mhalla Ahmed, Khouadja Sabria, Hannachi Ibtissem, Alshaikheid Mohammed, Slama Ahlem, Ben Fredj Nadia, Ben Fadhel Najeh, Ben Romdhane Haifa, Chaabane Amel, Boughattas Naceur A, Gaha Lotfi, Zarrouk Lazhar, Aouam Karim

Abstract excerpt

Clozapine (Clz) is an atypical antipsychotic, which its pharmacokinetics can be influenced by several factors. The CYP1A2 and CYP2C19, major enzymes implicated in Clz metabolism, present an interethnic variation on their activity caused by single nucleotide polymorphisms (SNPs). The present study investigated the influence of genetic and nongenetic factors on Clz pharmacokinetics in a southern Mediterranean...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Clozapine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A2

Share to Cytochrome P-450 CYP2C19

Share to Genotyping Techniques

Share to Schizophrenia

Share to Tunisia

Share to Young Adult

Source

Identifiers

PMID: 33731885
DOI: 10.1038/s41397-021-00231-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.PMID 33731885Read ↗

The Potential Role of POR*28 and CYP1A2*F Genetic Variations and Lifestyle Factors on Clozapine and N-DesmethylClozapine Plasma Levels in Schizophrenia Patients.Semantic proximity Read ↗

Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.Semantic proximity Read ↗

Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.Semantic proximity Read ↗

Effect of Organic Anion Transporting Polypeptide 1B1 on Plasma Concentration Dynamics of Clozapine in Patients with Treatment-Resistant Schizophrenia.Semantic proximity Read ↗

Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis.Semantic proximity Read ↗

Effects of a Novel UGT2B Haplotype and UGT1A4*3 Allele Variants on Glucuronidation of Clozapine In vivo.Semantic proximity Read ↗

Genetic and Clinical Factors Affecting Plasma Clozapine ConcentrationSemantic proximity Read ↗

Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an updateSemantic proximity Read ↗

The Role of Pharmacogenetic Testing in Optimizing Antipsychotic TherapySemantic proximity Read ↗

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Semantic proximity Read ↗

Modulatory effects of valproic acid and UGT polymorphisms on norclozapine plasma levels in clozapine-treated patients with schizophrenia.Semantic proximity Read ↗

Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.